Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies

References

• Geudens I, Gerhardt H. Coordinating cell behaviour during blood vessel formation. Development. 2011;138:4569–4583.
   PubMed Web of Science ®Google Scholar
• Núñez-Gómez E, Pericacho M, Ollauri-Ibáñez C, et al. The role of endoglin in post-ischemic revascularization. Angiogenesis. 2017;20:1–24.
   PubMed Web of Science ®Google Scholar
• Tímár J, Döme B, Fazekas K, et al. Angiogenesis-dependent diseases and angiogenesis therapy. Pathol Oncol Res. 2001;7:85–94.
   PubMedGoogle Scholar
• Yoo SY, Kwon SM. Angiogenesis and its therapeutic opportunities. Mediators Inflamm. 2013.
   Web of Science ®Google Scholar
• Zachary I, Morgan RD. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart. 2011;97:181–189.
   PubMed Web of Science ®Google Scholar
• Chu H, Wang Y. Therapeutic angiogenesis: controlled delivery of angiogenic factors. Ther Deliv. 2012;3:693–714.
   PubMedGoogle Scholar
• Rosen LS, Gordon MS, Robert F, et al. Endoglin for targeted cancer treatment. Curr Oncol Rep. 2014;365.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–974.
   PubMed Web of Science ®Google Scholar
• Cheifetz S, Bellón T, Calés C, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267:19027–19030.
   PubMed Web of Science ®Google Scholar
• Arthur HM, Ure J, Smith AJ, et al. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol. 2000;217:42–53.
   PubMed Web of Science ®Google Scholar
• Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534–1537.
   PubMed Web of Science ®Google Scholar
• Park S, Dimaio TA, Liu W, et al. Endoglin regulates the activation and quiescence of endothelium by participating in canonical and non-canonical TGF-β signaling pathways. J Cell Sci. 2013;126:1392–1405.
   PubMed Web of Science ®Google Scholar
• Jerkic M, Rodríguez-Barbero A, Prieto M, et al. Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc Res. 2006;69:845–854.
   PubMed Web of Science ®Google Scholar
• Van Laake LW, Van Den Driesche S, Post S, et al. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation. 2006;114:2288–2297.
   PubMed Web of Science ®Google Scholar
• Düwel A, Eleno N, Jerkic M, et al. Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice. Tumor Biol. 2006;28:1–8.
   PubMed Web of Science ®Google Scholar
• Seghers L, De Vries MR, Pardali E, et al. Shear induced collateral artery growth modulated by endoglin but not by ALK1. J Cell Mol Med. 2012;16:2440–2450.
   PubMed Web of Science ®Google Scholar
• Kuiper P, Hawinkels LJ, De Jonge-Muller ES, et al. Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2011;17:219–225.
   PubMed Web of Science ®Google Scholar
• Anderberg C, Cunha SI, Zhai Z, et al. Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med. 2013;210:563–579.
   PubMed Web of Science ®Google Scholar
• Barnett JM, Suarez S, McCollum GW, et al. Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization. Invest Ophthalmol Vis Sci. 2014;55:6490–6498.
   PubMed Web of Science ®Google Scholar
• Rossi E, Sanz-Rodriguez F, Eleno N, et al. Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood. 2013;121:403–415.
   PubMed Web of Science ®Google Scholar
• Rossi E, Smadja DM, Boscolo E, et al. Endoglin regulates mural cell adhesion in the circulatory system. Cell Mol Life Sci. 2016;73:1715–1739.
   PubMed Web of Science ®Google Scholar
• Castonguay R, Werner ED, Matthews RG, et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem. 2011;286:30034–30046.
   PubMed Web of Science ®Google Scholar
• Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: a clinical analysis. J Med Genet. 1992;29:527–530.
   PubMed Web of Science ®Google Scholar
• McDonald J, Wooderchak-Donahue W, VanSant Webb C, et al. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015;6:1.
   PubMed Web of Science ®Google Scholar
• Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91:66–67.
   PubMed Web of Science ®Google Scholar
• Dingenouts CKE, Goumans MJ, Bakker W. Mononuclear cells and vascular repair in HHT. Front Genet. 2015;6:114.
   PubMed Web of Science ®Google Scholar
• Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010;16:420–428.
   PubMed Web of Science ®Google Scholar
• Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes. 2017;9:434–449.
   PubMed Web of Science ®Google Scholar
• Liu Z-J, Velazquez OC. Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. Antioxid Redox Signal. 2008;10:1869–1882.
   PubMed Web of Science ®Google Scholar
• Annex BH. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol. 2013;10:387–396.
   PubMed Web of Science ®Google Scholar
• Reddy AM, Kwak BK, Shim HJ, et al. A long-term outcome of therapeutic angiogenesis by transplantation of peripheral blood stem cells in critical limb ischemia after interventional revascularization. Diagn Interv Radiol. 2013;19:76–80.
   PubMed Web of Science ®Google Scholar
• Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA, et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 2010;8:86.
   PubMed Web of Science ®Google Scholar
• Blann AD, Wang JM, Wilson PB, et al. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis. 1996;120:221–226.
   PubMed Web of Science ®Google Scholar
• Rathouska J, Vecerova L, Strasky Z, et al. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res. 2011;64:53–59.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–649.
   PubMed Web of Science ®Google Scholar
• Valbuena-Diez AC, Blanco FJ, Oujo B, et al. Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation. 2012;126:2612–2624.
   PubMed Web of Science ®Google Scholar
• Barbagallo M, Resnick LM, Dominguez LJ, et al. Diabetes mellitus, hypertension and ageing: the ionic hypothesis of ageing and cardiovascular-metabolic diseases. Diabetes Metab. 1997;23:281–294.
   PubMed Web of Science ®Google Scholar
• Abete P, Napoli C, Santoro G, et al. Age-related decrease in cardiac tolerance to oxidative stress. J Mol Cell Cardiol. 1999;31:227–236.
   PubMed Web of Science ®Google Scholar
• Edelberg JM, Reed MJ. Aging and angiogenesis. Front Biosci J Virtual Libr. 2003;8:s1199–209.
   PubMed Web of Science ®Google Scholar
• Blanco FJ, Grande MT, Langa C, et al. S-Endoglin upregulation as a senescence marker of endothelial cells and its role in vascular pathology. Haematol Meet Reports. 2009;3:9.
   Google Scholar
• Velasco S, Alvarez-Muñoz P, Pericacho M, et al. L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci. 2008;121:913–919.
   PubMed Web of Science ®Google Scholar
• Gabrielli A, Avvedimento EV, Krieg T. Mechanisms of disease. SCLERODERMA. N Engl J Med. 2009;19:1989–2003.
   Web of Science ®Google Scholar
• Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol. 2011;6:509–537.
   PubMed Web of Science ®Google Scholar
• Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996;98:785–792.
   PubMed Web of Science ®Google Scholar
• Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol. 2010;6:453–460.
   PubMed Web of Science ®Google Scholar
• Dharmaplltni AASSK, Smith MD, Ahern MJ, et al. The TGF ~ Receptor Endoglin in sys ­ temic sclerosis. Asian Pacific J Allergy Immunol. 2001;19:275–282.
   PubMed Web of Science ®Google Scholar
• Li C, Issa R, Kumar P, et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003;116:2677–2685.
   PubMed Web of Science ®Google Scholar
• Coral-Alvarado PX, Garces MF, Caminos JE, et al. Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol. 2010;2010.
   Google Scholar
• Paauwe M, Ten Dijke P, Hawinkels LJAC. Endoglin for tumor imaging and targeted cancer therapy. Expert Opin Ther Targets. 2013;17:421–435.
   PubMed Web of Science ®Google Scholar
• Fonsatti E, Jekunen AP, Kairemo KJA, et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res. 2000;6:2037–2043.
   PubMed Web of Science ®Google Scholar
• Lin H, Huang CC, Ou YC, et al. High immunohistochemical expression of TGF-beta1 predicts a poor prognosis in cervical cancer patients who harbor enriched endoglin microvessel density. Int J Gynecol Pathol. 2012;31:482–489.
   PubMed Web of Science ®Google Scholar
• Pérez-Gómez E, Villa-Morales M, Santos J, et al. A role for endoglin as a suppressor of malignancy during mouse skin carcinogenesis. Cancer Res. 2007;67:10268–10277.
   PubMed Web of Science ®Google Scholar
• Duarte CW, Black AW, Lucas F L, et al. Cancer incidence in patients with hereditary hemorrhagic telangiectasia. J Cancer Res Clin Oncol. 2016;143:209–214.
   PubMed Web of Science ®Google Scholar
• Hosman AE, Devlin HL, Silva BM, et al. Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis. 2013;8:195.
   PubMed Web of Science ®Google Scholar
• Duarte CW, Murray K, Lucas FL, et al. Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer Epidemiol Biomarkers Prev. 2014;23:117–125.
   PubMed Web of Science ®Google Scholar
• Kovacs K, Marra KV, Yu G, et al. Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Investig Ophthalmol Vis Sci. 2015;56:6523–6530.
   PubMed Web of Science ®Google Scholar
• Mahmoud M, Allinson KR, Zhai Z, et al. Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res. 2010;106:1425–1433.
   PubMed Web of Science ®Google Scholar
• Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114–1123.
   PubMed Web of Science ®Google Scholar
• Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J VascSurg. 2002;35:930–936.
   PubMed Web of Science ®Google Scholar
• Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008;118:58–65.
   PubMed Web of Science ®Google Scholar
• Niemi H, Honkonen K, Korpisalo P, et al. HIF-1 alpha and HIF-2 alpha induce angiogenesis and improve muscle energy recovery. Eur J Clin Invest. 2014;44:989–999.
   PubMed Web of Science ®Google Scholar
• Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res. 2015;116:1561–1578.
   PubMed Web of Science ®Google Scholar
• Sanada F, Taniyama Y, Kanbara Y, et al. Gene therapy in peripheral artery disease. Expert Opin Biol Ther. 2015;15:381–390.
   PubMed Web of Science ®Google Scholar
• Silvestre J-S, Smadja DM, Lévy BI. Postischemic revascularization: from cellular and molecular mechanisms to clinical applications. Physiol Rev. 2013;93:1743–1802.
   PubMed Web of Science ®Google Scholar
• Muñoz-Félix JM, González-Núñez M, Martínez-Salgado C, et al. TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25years of trials and tribulations? Pharmacol Ther. 2015;156:44–58.
   PubMed Web of Science ®Google Scholar
• Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359:2053–2058.
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Mohler E, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J. 2003;145:1114–1118.
   PubMed Web of Science ®Google Scholar
• Kolakowski SJ, Berry MF, Atluri P, et al. Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy. J Card Surg. 2006;21:559–564.
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967.
   PubMed Web of Science ®Google Scholar
• Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1–E7.
   PubMed Web of Science ®Google Scholar
• Asahara T, Kawamoto A, Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells. 2011;29:1650–1655.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434–438.
   PubMed Web of Science ®Google Scholar
• Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103:2776–2779.
   PubMed Web of Science ®Google Scholar
• Schatteman GC, Hanlon HD, Jiao C, et al. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest. 2000;106:571–578.
   PubMed Web of Science ®Google Scholar
• Moriya J, Minamino T, Tateno K, et al. Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia. Circ Cardiovasc Interv. 2009;2:245–254.
   PubMed Web of Science ®Google Scholar
• Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J. 2008;156:1010–1018.
   PubMed Web of Science ®Google Scholar
• Seemann I, Te Poele JAM, Hoving S, et al. Mouse bone marrow-derived endothelial progenitor cells do not restore radiation-induced microvascular damage. ISRN Cardiol. 2014;2014:1–7.
   Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186.
   PubMed Web of Science ®Google Scholar
• Osaadon P, Fagan XJ, Lifshitz T, et al. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond). 2014;28:510–520.
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.
   PubMed Web of Science ®Google Scholar
• Haruta Y, Seon BKS. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci U S A. 1986;83:7898–7902.
   PubMed Web of Science ®Google Scholar
• Nolan-Stevaux O, Zhong W, Culp S, et al. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS One. 2012;7.
   PubMed Web of Science ®Google Scholar
• Liu Y, Starr MD, Brady JC, et al. Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. Cancer Med. 2014;3:580–591.
   PubMed Web of Science ®Google Scholar
• TRACON Pharmaceuticals (http://www.traconpharma.com)
   Google Scholar
• Liu Y, Tian H, Blobe GC, et al. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Invest New Drugs. 2014;32:851–859.
   PubMed Web of Science ®Google Scholar
• Dolinsek T, Markelc B, Sersa G, et al. Multiple delivery of siRNA against Endoglin into murine mammary adenocarcinoma prevents angiogenesis and delays tumor growth. PLoS One. 2013;8.
   PubMed Web of Science ®Google Scholar
• Tesic N, Kamensek U, Sersa G, et al. Endoglin (CD105) silencing mediated by shRNA under the control of Endothelin-1 promoter for targeted gene therapy of melanoma. Mol Ther Nucleic Acids. 2015;4:e239.
   PubMedGoogle Scholar
• Stimac M, Dolinsek T, Lampreht U, et al. Gene electrotransfer of plasmid with tissue specific promoter encoding shRNA against endoglin exerts antitumor efficacy against murine TS/A tumors by vascular targeted effects. PLoS One. 2015;10.
   PubMed Web of Science ®Google Scholar
• Dolinsek T, Sersa G, Prosen L, et al. Electrotransfer of plasmid DNA encoding an anti-mouse endoglin (CD105) shRNA to B16 melanoma tumors with low and high metastatic potential results in pronounced anti-tumor effects. Cancers (Basel). 2015;8.
   PubMed Web of Science ®Google Scholar
• Stimac M, Kamensek U, Cemazar M, et al. Tumor radiosensitization by gene therapy against endoglin. Cancer Gene Ther. 2016;23:214–220.
   PubMed Web of Science ®Google Scholar